Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Novartis AG reported a strong financial performance for the second quarter of 2025, marked by double-digit sales growth, core margin expansion, and a subsequent upgrade to its full-year guidance regarding core operating income.</li><li>The company delivered robust sales growth of 11% in constant currency, while core operating income surged by 21% in constant currency.</li><li>This financial momentum is largely attributed to significant growth in its priority brands.</li></ul>

Novartis AG reported a strong financial performance for the second quarter of 2025, marked by double-digit sales growth, core margin expansion, and a subsequent upgrade to its full-year guidance regarding core operating income.The company delivered robust sales growth of 11% in constant currency, while core operating income surged by 21% in constant currency.This financial momentum is largely attributed to significant growth in its priority brands.

Novartis Gears Up for a Pipeline Surge—How Remibrutinib

<ul><li>Novartis, a global pharmaceutical leader, reported its Q1 2025 results with impressive financial metrics combined with significant advancements in its pharmaceutical portfolio.</li><li>The company's operational metrics showcased robust performance, with net sales increasing by 15% and core operating income growing by 27%.</li><li>This resulted in a core margin of 42.1%, up by 400 basis points, indicating effective cost management and revenue growth strategies.</li></ul>

Novartis, a global pharmaceutical leader, reported its Q1 2025 results with impressive financial metrics combined with significant advancements in its pharmaceutical portfolio.The company's operational metrics showcased robust performance, with net sales increasing by 15% and core operating income growing by 27%.This resulted in a core margin of 42.1%, up by 400 basis points, indicating effective cost management and revenue growth strategies.

Novartis AG: The Advancements & Challenges in Pelacarsen Development & Other Major Drivers!

<ul><li>Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its history.</li><li>The company recorded a 16% increase in sales in the fourth quarter and a 29% rise in core operating income, both in constant currency.</li><li>For the full year, sales grew 12%, while core operating income expanded by 22%, with an operating margin reaching 38.7%.</li></ul>

Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its history.The company recorded a 16% increase in sales in the fourth quarter and a 29% rise in core operating income, both in constant currency.For the full year, sales grew 12%, while core operating income expanded by 22%, with an operating margin reaching 38.7%.

Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>Novartis offers an agreed €68/share, 89% premium, for <a href="https://www.smartkarma.com/entities/morphosys-ag-91f7c8f8-f418-4db5-953e-ec2206d64e67" target="_blank" data-smartkarma-citation="entities:27120:1" rel="noopener">MorphoSys AG (MOR US)</a> in a bet that pelabrisib could become a blockbuster to treat myelofibrosis (possibly reaching peak sales of $1.1-1.5 billion).</li>
<li>Considering that the shares of Morphosys were trading in the low teens in November, I believe that shareholders will be happy to part with the shares.</li>
<li>Spread (gross/annualised) is 4.65%/18.09% (assuming settlement by 20 May). Novartis believes pelabrisib is definitely worth the risk. <strong>Long.</strong>
</li>
</ul>


Novartis offers an agreed €68/share, 89% premium, for MorphoSys AG (MOR US) in a bet that pelabrisib could become a blockbuster to treat myelofibrosis (possibly reaching peak sales of $1.1-1.5 billion).
Considering that the shares of Morphosys were trading in the low teens in November, I believe that shareholders will be happy to part with the shares.
Spread (gross/annualised) is 4.65%/18.09% (assuming settlement by 20 May). Novartis believes pelabrisib is definitely worth the risk. Long.



Novartis Strikes for Possible Myelofibrosis Blockbuster

Switzerland

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novartis (NOVN SW)

Novartis Gears Up for a Pipeline Surge—How Remibrutinib

Novartis AG reported a strong financial performance for the second quarter of 2025, marked by double-digit sales growth, core margin expansion,...

Baptista Research

Novartis AG: The Advancements & Challenges in Pelacarsen Development & Other Major Drivers!

Novartis, a global pharmaceutical leader, reported its Q1 2025 results with impressive financial metrics combined with significant advancements in...

Baptista Research

Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?

Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its...

Baptista Research

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Novartis Strikes for Possible Myelofibrosis Blockbuster

Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...

Jesus Rodriguez Aguilar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Novartis Gears Up for a Pipeline Surge—How Remibrutinib

Novartis AG reported a strong financial performance for the second quarter of 2025, marked by double-digit sales growth, core margin expansion,...

Baptista Research

Novartis AG: The Advancements & Challenges in Pelacarsen Development & Other Major Drivers!

Novartis, a global pharmaceutical leader, reported its Q1 2025 results with impressive financial metrics combined with significant advancements in...

Baptista Research

Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?

Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its...

Baptista Research

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Novartis Strikes for Possible Myelofibrosis Blockbuster

​Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...

Jesus Rodriguez Aguilar

Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...